TLDR:
- Forbion co-leads US$157m Series B in Engrail Therapeutics with other investors.
- Engrail is developing therapies for anxiety disorders, depression, PTSD, and neurodegenerative diseases.
European life sciences VC firm, Forbion, has co-led a US$157m Series B financing round in Engrail Therapeutics, a US based precision neuroscience company. Forbion joins other new investors, US-based F-Prime Capital and Norwest Venture Partners to co-lead the deal, with RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc, Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences also participating in the oversubscribed round. Since its inception in 2019, Engrail has raised over US$220m. Funding from the Series B round will accelerate the advancement of the company’s pipeline through multiple stages of clinical development. Engrail is developing therapies for the treatment of anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases.
